Ludvik B, Giorgino F, Jdar E et al (2021) Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial
In 2022, Eli Lilly launched Tirzepatide, a novel dual GLP-1RA/GIPR agonist administered once weekly by subcutaneous injection that activates both GLP-1 and GIP receptors
For example, a pharmacy may make a liquid version of a drug that only comes in pill form for a patient who has trouble swallowing
Complimentary Purchase Kit Every qualifying vial includes a complimentary purchase kit at no additional cost
Changing habits is a hard thing to suddenly do, but taking small steps to change the way you eat goes a long way in assisting with weight maintenance